Board
The Board of Directors of Oscotec serves as the Company’s key decision-making body, reviewing and approving major management matters in accordance with the Board of Directors Regulations.
Composed of executive and independent directors elected by shareholders, the Board supports balanced decision-making through diverse expertise and strengthens independent oversight of management.
The Board consists of seven members: five executive directors and two independent directors,
who have no material business relationships or interests with the Company or its largest shareholder.
Executive Director
Taeyoung Yoon
Expertise
Drug Discovery · R&D Strategy
Key Experience
- Senior Researcher, Novartis
- Head of Innovative Drug
- Research Institute, Dong-A ST
- Head of Innovative Drug Research Institute, Dong-A Socio Holdings
- Current CEO, Oscotec Inc.
Executive Director
Sanghyun Lee
Expertise
Management · Corporate Strategy
Key Experience
- M.A. in Business Administration, Dankook University
- Executive Vice President, Oscotec Inc.
- Current CEO, Oscotec Inc.
Executive Director
Youngshin Kwak
Expertise
Drug Discovery · R&D Management
Key Experience
- Senior Researcher, Novartis
- Principal Researcher, Korea
- Research Institute of Bioscience and Biotechnology
- Professor, College of Pharmacy, Korea University
- Executive Director, Life Sciences Division, LG Chem
- Head of Hyojong Research Institute, Chong Kun Dang
- Current Vice President, Oscotec Inc.
Executive Director
Dongjun Shin
Expertise
Finance · Corporate Strategy
Key Experience
- Ph.D. in Economics, Chung-Ang University
- Head of Investment Strategy, Trading Division, Mirae Asset Securities
- Head of Asset Allocation
- Strategy, KB Securities Research Center
- Head of Research Center, KB Securities
- Head of WM Solutions & WM Investment Strategy, KB Securities
- Current Executive Vice President, Oscotec Inc.
Executive Director
Jinhyung Kang
Expertise
Oncology · Clinical · Medical Strategy
Key Experience
- M.D. and Ph.D., The Catholic University of Korea
- Professor, Seoul St. Mary’s Hospital
- Former President, Korean Association for Lung Cancer
- Head, Oncology Strategic Advisory Group, NIFDS
- Member, Investment Review Committee, Korea Drug Development Fund
- Member, Pharmaceutical Benefit Evaluation Committee, HIRA
- Current Executive Vice President, Oscotec Inc.
Independent Director
Kyusik Kim
Expertise
Governance · Legal · Capital Markets
Key Experience
-
College of Law, Seoul National University
-
Legal Counsel, Financial Supervisory Service
-
Managing Attorney, KSA Joint Law Office
-
Director, Korea Corporate Governance Forum (Former Chairman)
-
Independent Director, SM Entertainment
-
Portfolio Manager, Vista Global Asset Management
-
Current Independent Director, Oscotec Inc.
Independent Director
Kyungsup Lee
Expertise
Legal · Finance · Risk Management
Key Experience
- Korea University, College of Law
- Completed graduate coursework in Law, Korea University
- Judge, Eastern Branch of Seoul District Court
- Judge, Seoul Central District Court
- Partner Attorney, Barun Law LLC
- Current Independent Director, Oscotec Inc.
Board Operating Principles
| Category | Term of Office | Details |
|---|---|---|
|
Appointment of Directors |
Elected by Shareholders |
Directors are elected at the General Meeting of Shareholders in accordance with the Articles of Incorporation and applicable laws. |
|
Term of Office |
3 years |
Directors serve a three-year term in accordance with the Articles of Incorporation. |
|
Chair of the Board |
Appointed by the Board |
The Chair is appointed from among the executive directors by Board resolution. |
|
Board Resolutions |
Majority Approval |
Resolutions require a majority of directors to be present and a majority of those present to approve. Directors with a special interest may not vote. |
Board Skills Matrix
| Category | Sanghyun Lee | Taeyoung Yoon | Youngshin Kwak | Dongjun Shin | Jinhyung Kang | Kyusik Kim | Kyungsup Lee |
|---|---|---|---|---|---|---|---|
| (Executive Director) |
(Executive Director) |
(Executive Director) |
(Executive Director) |
(Executive Director) |
(Independent Director) |
(Independent Director) |
|
|
Management / Leadership |
○ | ○ | ○ | ○ | ○ | - | - |
|
Industry Experience |
- | ○ | ○ | - | ○ | - | - |
|
Corporate Value |
○ | ○ | ○ | - | ○ | - | - |
|
Finance / Accounting |
○ | - | - | ○ | - | - | - |
|
Risk Management |
○ | - | - | ○ | - | ○ | - |
| Legal | - | - | - | - | - | ○ | ○ |
| ESG | - | - | - | ○ | - | ○ | - |
| Gender | Male | Male | Male | Male | Male | Male | Male |
| Meeting Date | Agenda | Resolution | Attendance |
|---|---|---|---|
| Jan. 31, 2025 | Approval of 27th Term Separate Financial Statements | Approved | 4/4 |
| Feb. 26, 2025 | 1.Approval of 27th Term Consolidated Financial Statements | Approved | 4/4 |
| 2.Resolution to Convene General Shareholders' Meeting | Approved | ||
| 3.Report on Internal Accounting Control Evaluation | Approved | ||
| Mar. 10, 2025 | Adoption of Electronic Voting for 27th Annual General Meeting | Approved | 4/4 |
| Apr. 14, 2025 | Appointment of Co-CEOs | Approved | 4/4 |
| Aug. 12, 2025 | Semi-Annual Regular Board Meeting | Approved | 4/4 |
| Sep. 29, 2025 | Amendment to Joint R&D Agreement | Approved | 4/4 |
| Oct. 22, 2025 | Resolution to Convene Extraordinary General Meeting | Approved | 4/4 |
| Nov. 13, 2025 | Finalization of Detailed Agenda for General Meeting Convocation | Approved | 4/4 |
| Dec. 17, 2025 | Determination of 28th Term Auditor's Remuneration | Approved | 4/4 |